National Institutes of Health: HIV Infections trials

The registry lists 831 HIV Infections studies with National Institutes of Health as lead sponsor. 9 are open to participants now and 114 have results posted.

Phase 1 352Phase 2 202Phase 3 66Phase 4 11No phase 245(a study in two phases counts in both)

Studies

Page 5 of 9. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With DidanosineCompletedNCT00026676
• Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SCCompletedNCT00026624Phase 1
• Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral LoadCompletedNCT00025922
• Intermittent vs. Continuous HAART to Treat Chronic HIV InfectionCompletedNCT00025909Phase 3
• Tenofovir Disoproxil Fumarate to Treat Pediatric HIVCompletedNCT00024986Phase 1
• Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV InfectionCompletedNCT00023153Phase 3
• HIV Prevention Preparedness Study in Russia, China, and IndiaCompletedNCT00021775
• Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIVWithdrawnNCT00021762Phase 2
• Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV TreatmentWithdrawnNCT00021489Phase 2
• Acupressure to Treat Nausea and Vomiting in HIV/AIDS PatientsCompletedNCT00017823Phase 1
• Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant WomenCompletedNCT00017797
• Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV DrugsCompletedNCT00017771
• Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During PregnancyCompletedNCT00017719Phase 3
• Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIVCompletedNCT00016783
• Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected WomenCompletedNCT00016601Not applicable
• Effects of BufferGel and PRO 2000/5 Gel in MenCompletedNCT00016536Phase 1
• Effect of Interleukin-2 on HIV Treatment InterruptionCompletedNCT00015704Not applicable
• Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV CoinfectionCompletedNCT00015652Not applicable
• Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination RegimenCompletedNCT00014937Not applicable
• A Study of Immune System Activity in Healthy AdultsCompletedNCT00014053
• Zidovudine and Lamivudine Given Once Versus Twice DailyCompletedNCT00014014Phase 1
• HIV Maintenance Therapy With T-20 During HAART InterruptionCompletedNCT00013884Phase 2
• Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral LoadCompletedNCT00013663Phase 2
• Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionCompletedNCT00013520Phase 3
• Ritonavir and Indinavir in Children Failing Other Anti-HIV TreatmentCompletedNCT00012519Phase 1/2
• The Effect of Milk Thistle on the Pharmacokinetics of IndinavirCompletedNCT00011635Phase 1
• Blood Levels of Abacavir After One Dose in HIV-Infected Children and AdolescentsCompletedNCT00011479Phase 1
• Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV TreatmentWithdrawnNCT00011128Phase 3
• Effects of Storage on Lactate in Blood SamplesCompletedNCT00011050
• ALVAC-HIV vCP1452 Alone and Combined With MN rgp120CompletedNCT00011037Phase 2
• Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIVCompletedNCT00011011Phase 1/2
• Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal FatCompletedNCT00009555Phase 4
• Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral TherapyCompletedNCT00009256
• Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug TherapyWithdrawnNCT00008866Phase 2
• HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV DrugsCompletedNCT00007488
• Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in UgandaCompletedNCT00007423Phase 1
• Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/BCompletedNCT00007332Phase 2
• Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsCompletedNCT00006617Not applicable
• Capravirine to Treat Children With HIV InfectionCompletedNCT00006519Phase 1
• A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 YearsCompletedNCT00006509Phase 1
• Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452CompletedNCT00006495Phase 1
• Study of Tests to Evaluate Effectiveness of Anti-HIV DrugsCompletedNCT00006494
• A Comparison of Two Tests for Anti-HIV Drug ResistanceCompletedNCT00006490
• Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV InfectionCompletedNCT00006443Not applicable
• The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected PatientsCompletedNCT00006442
• Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIVCompletedNCT00006441Not applicable
• A Test of Behavioral Intervention for Women at High Risk for HIV InfectionCompletedNCT00006440
• Effects of Home Visits on Medication Adherence in Children and Youth With HIVStatus unknownNCT00006439Not applicable
• Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionWithdrawnNCT00006339Phase 2
• Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive ChildrenCompletedNCT00006325Phase 1
• Hormonal Birth Control and the Risk of Acquiring HIVCompletedNCT00006324Not applicable
• Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant WomenCompletedNCT00006320Phase 1
• Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug CombinationCompletedNCT00006291Phase 2
• The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 MonthsCompletedNCT00006279Phase 1
• Safety and Tolerability of the Vaginal Gel PRO 2000/5CompletedNCT00006207Phase 1
• Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy SyndromeCompletedNCT00006185Phase 1
• A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV InfectionCompletedNCT00006154Phase 3
• A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug TreatmentCompletedNCT00006152Phase 2
• A Study of HIV-Disease Development in AgingCompletedNCT00006144Phase 2
• Growth Hormone Treatment of Children With HIV-Associated Growth FailureCompletedNCT00006143Not applicable
• A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their BabiesCompletedNCT00006075Phase 2
• Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsCompletedNCT00006066Phase 1
• A Comparison of Two Anti-HIV Treatment PlansCompletedNCT00005915
• Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug TherapyCompletedNCT00005779Phase 1
• Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersCompletedNCT00005762Not applicable
• Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug CombinationCompletedNCT00005758Phase 3
• Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV DrugsCompletedNCT00005673Phase 1
• HIV Diversity and Pathogenesis in Donor-Recipient ClustersCompletedNCT00005360
• Cardiac Autonomic Control in Children of HIV Positive MothersCompletedNCT00005353
• Effectiveness of AIDS Antibody ScreeningCompletedNCT00005303
• Transfusion Safety Study (TSS)CompletedNCT00005301
• Retrovirus Epidemiology Donor Study I (REDS I)CompletedNCT00005278
• Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2)CompletedNCT00005274
• Pulmonary Complications of HIV Infection Study (PACS)CompletedNCT00005273
• HIV-Associated Heart DiseaseCompletedNCT00005229
• AIDS-Associated Heart Disease -- Incidence and EtiologyCompletedNCT00005228
• AIDS-Associated CardiomyopathyCompletedNCT00005227
• Observing Patients With Early HIV InfectionCompletedNCT00005020
• Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV DrugsCompletedNCT00004855Not applicable
• Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus RetinitisCompletedNCT00004794Phase 2
• The Metabolic Effects of Protease Inhibitors in HIV Infected ChildrenCompletedNCT00004739Not applicable
• The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIVCompletedNCT00004735Not applicable
• Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-WastingCompletedNCT00004664Not applicable
• Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV InfectionsCompletedNCT00004276Phase 2
• Once-Daily Drug Regimen for HIV-Infected PatientsCompletedNCT00001968Phase 1
• Intermittent Versus Continuous Medication in the Treatment of HIVCompletedNCT00001967Phase 4
• A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral TherapyCompletedNCT00001948
• Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral TherapyCompletedNCT00001899
• Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase InhibitorCompletedNCT00001826
• Combination Drug Treatment of Pediatric HIV InfectionCompletedNCT00001818Phase 1
• Drug Interactions Among Anti-HIV AgentsCompletedNCT00001766Phase 1
• Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex InfectionCompletedNCT00001763Phase 1
• Magnetic Resonance Imaging of the Face and BonesCompletedNCT00001762
• Continued Antiretroviral Therapy With Abacavir, Amprenavir and EfavirenzCompletedNCT00001758Phase 2
• Influences on HIV Infected Subjects' Willingness to Participate in Research and Ability to Give Informed ConsentCompletedNCT00001717
• A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their MothersCompletedNCT00001699
• A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and StavudineCompletedNCT00001688Phase 2
• A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus ConcentrationsCompletedNCT00001681
• Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected PatientsCompletedNCT00001650
• White Blood Cell Infusions to Treat HIV InfectionCompletedNCT00001647Phase 1